Abstract: The present disclosure is directed to methods of purifying a dulaglutide composition. For example, the methods comprise loading the dulaglutide composition in-line with a buffer B solution onto a hydrophobic interaction chromatography (HIC) column in a downflow direction, washing the HIC column with a buffer mixture of a buffer A solution and the buffer B solution in the downflow direction, and eluting dulaglutide from the HIC column. A linear gradient of a percentage of the buffer A and buffer B solutions is used for eluting dulaglutide, which is then followed by an isocratic hold based on a UV absorbance reading of an eluate. The methods further comprise maintaining the isocratic hold until a front side cut is made, and then dropping the buffer B solution for dulaglutide to elute from the HIC column.
| # | Name | Date |
|---|---|---|
| 1 | 202517061709-STATEMENT OF UNDERTAKING (FORM 3) [27-06-2025(online)].pdf | 2025-06-27 |
| 2 | 202517061709-Sequence Listing in txt [27-06-2025(online)].txt | 2025-06-27 |
| 3 | 202517061709-Sequence Listing in PDF [27-06-2025(online)].pdf | 2025-06-27 |
| 4 | 202517061709-REQUEST FOR EXAMINATION (FORM-18) [27-06-2025(online)].pdf | 2025-06-27 |
| 5 | 202517061709-PRIORITY DOCUMENTS [27-06-2025(online)].pdf | 2025-06-27 |
| 6 | 202517061709-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [27-06-2025(online)].pdf | 2025-06-27 |
| 7 | 202517061709-FORM 18 [27-06-2025(online)].pdf | 2025-06-27 |
| 8 | 202517061709-FORM 1 [27-06-2025(online)].pdf | 2025-06-27 |
| 9 | 202517061709-DRAWINGS [27-06-2025(online)].pdf | 2025-06-27 |
| 10 | 202517061709-DECLARATION OF INVENTORSHIP (FORM 5) [27-06-2025(online)].pdf | 2025-06-27 |
| 11 | 202517061709-COMPLETE SPECIFICATION [27-06-2025(online)].pdf | 2025-06-27 |
| 12 | 202517061709-FORM-26 [29-07-2025(online)].pdf | 2025-07-29 |